HBM Healthcare Investments Reports CHF 19 Million Net Profit

HBM Healthcare Investments AG has announced a net profit of CHF 19 million for the financial year 2024/2025, concluding on 31 March. The company's net asset value per share increased by 1.5 percent to CHF 244.41, despite a slight decrease in share price by 2.6 percent.

The biotech sector faced challenges, with indices like the Nasdaq Biotech Index and S&P Biotech ETF falling by 5.2 percent and 16.0 percent respectively. However, HBM Healthcare's performance remained positive due to strategic acquisitions and a successful IPO. Notably, Yellow Jersey Therapeutics and Dren Bio were acquired, and SAI Life Sciences completed an IPO in India.

The performance of key investments Swixx Biopharma and Cathay Biotech also bolstered the results. Despite negative currency effects impacting the results by 1.8 percent, the company's financial achievement stands out amid sector-wide difficulties.